Romiplostim as a treatment for immune thrombocytopenia: a review

References

• TerrellDRBeebeLAVeselySKNeasBRSegalJBGeorgeJNThe incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reportsAm J Hematol201085317418020131303
   PubMed Web of Science ®Google Scholar
• ImbachPAkatsukaJBlanchetteVSImmunthrombocytopenic purpura as a model for pathogenesis and treatment of autoimmunityEur J Pediatr19951549 Suppl 4S60S648529713
   PubMed Web of Science ®Google Scholar
• FrederiksenHSchmidtKThe incidence of idiopathic thrombocytopenic purpura in adults increases with ageBlood199994390991310419881
   PubMed Web of Science ®Google Scholar
• NeylonAJSaundersPWHowardMRProctorSJTaylorPRNorthern Region Haematology GroupClinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patientsBr J Haematol2003122696697412956768
   PubMed Web of Science ®Google Scholar
• BurtSPurpura hemorrhagiva, or morhus maculosus of WerlhofN Engl J Med1900143441444
   Google Scholar
• HarringtonWJMinnichVHollingsworthJWMooreCVDemonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpuraJ Lab Clin Med195138111014850832
   PubMed Web of Science ®Google Scholar
• ShulmanNRMarderVJWeinrachRSSimilarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studiesAnn N Y Acad Sci196512424995425214832
   PubMed Web of Science ®Google Scholar
• StockelbergDHouMJacobssonSKuttiJWadenvikHEvidence for a light chain restriction of glycoprotein Ib/IX and IIb/IIIa reactive antibodies in chronic idiopathic thrombocytopenic purpura (ITP)Br J Haematol19959011751797786782
   PubMed Web of Science ®Google Scholar
• HeRReidDMJonesCEShulmanNRExtracellular epitopes of platelet glycoprotein Ib alpha reactive with serum antibodies from patients with chronic idiopathic thrombocytopenic purpuraBlood19958610378937967579346
   PubMed Web of Science ®Google Scholar
• van LeeuwenEFvan der VenJTEngelfrietCPvon dem BorneAESpecificity of autoantibodies in autoimmune thrombocytopeniaBlood198259123267032627
   PubMed Web of Science ®Google Scholar
• BallemPJSegalGMStrattonJRGernsheimerTAdamsonJWSlichterSJMechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearanceJ Clin Invest198180133403597777
   PubMed Web of Science ®Google Scholar
• McMillanRLuikenGALevyRYelenoskyRLongmireRLAntibody against megakaryocytes in idiopathic thrombocytopenic purpuraJ Am Med Assoc2392324602462
   Web of Science ®Google Scholar
• HeRReidDMJonesCEShulmanNRSpectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpuraBlood1994834102410328111044
   PubMed Web of Science ®Google Scholar
• TarantinoMDGoldsmithGTreatment of acute immune thrombocytopenic purpuraSemin Hematol1998351 Suppl 128359523747
   PubMed Web of Science ®Google Scholar
• ProvanDStasiRNewlandACInternational consensus report on the investigation and management of primary immune thrombocytopeniaBlood2010115216818619846889
   PubMed Web of Science ®Google Scholar
• NeunertCLimWCrowtherMCohenASolbergLJrCrowtherMAAmerican Society of HematologyThe American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopeniaBlood2011117164190420721325604
   PubMed Web of Science ®Google Scholar
• GodeauBChevretSVaretBFrench ATIP Study GroupIntravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trialLancet20023599300232911809183
   PubMed Web of Science ®Google Scholar
• BlanchetteVSLukeBAndrewMA prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpuraJ Pediatr199312369899958229536
   PubMed Web of Science ®Google Scholar
• BeckCENathanPCParkinPCBlanchetteVSMacarthurCCorticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trialsJ Pediatr2005147452152716227040
   PubMed Web of Science ®Google Scholar
• PatelVLMahévasMLeeSYOutcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopeniaBlood2012119255989599522566601
   PubMed Web of Science ®Google Scholar
• BennettCMRogersZRKinnamonDDProspective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpuraBlood200610772639264216352811
   PubMed Web of Science ®Google Scholar
• MuellerBUBennettCMFeldmanHAPediatric Rituximab/ITP Study GroupGlaser Pediatric Research NetworkOne year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximabPediatr Blood Cancer200952225926218937333
   PubMed Web of Science ®Google Scholar
• WangJWileyJMLuddyRGreenbergJFeuersteinMABusselJBChronic immune thrombocytopenic purpura in children: assessment of rituximab treatmentJ Pediatr2005146221722115689912
   PubMed Web of Science ®Google Scholar
• ParodiERivettiEAmendolaGLong-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained responseBr J Haematol2009144455255819036077
   PubMed Web of Science ®Google Scholar
• ReinerAGersheimerTSlichterSJPulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpuraBlood19958523513587811992
   PubMed Web of Science ®Google Scholar
• SchiavottoCCastamannGRodeghieroFTreatment of idiopathic thrombocytopenic purpura (ITP) in patients with refractoriness to or with contraindication for corticosteroids and/or splenectomy with immunosuppressive therapy and danazolHaematologica1993786 Suppl 229348039755
   PubMedGoogle Scholar
• FaconTCaulierMTWattelEJouetJPBautersFFenauxPA randomized trial comparing vinblastine in slow infusion and by bolus iv injection in idiopathic thrombocytopenic purpura: a report on 42 patientsBr J Haematol19948636786808043455
   PubMed Web of Science ®Google Scholar
• PizzutoJAmbrizRTherapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and ThrombosisBlood1984646117911836388663
   PubMed Web of Science ®Google Scholar
• FigueroaMGehlsenJHammondDCombination chemotherapy in refractory immune thrombocytopenic purpuraN Engl J Med199332817122612298464433
   PubMed Web of Science ®Google Scholar
• WeinblattMEKochenJOrtegaJDanazol for children with immune thrombocytopenic purpuraAm J Dis Child198814212131713193195531
   PubMedGoogle Scholar
• MarwahaRKSinghRPGarewalGMarwahaNPrakashDSarodeRColchicine therapy in immune thrombocytopenic purpuraActa Paediatr Scand19907911111811202267933
   PubMed Web of Science ®Google Scholar
• StrotherSVZuckermanKSLoBuglioAFColchicine therapy for refractory idiopathic thrombocytopenic purpuraArch Intern Med198414411219822006541898
   PubMedGoogle Scholar
• IshiiHOhHUchidaYEffect of interferon (IFN) on refractory idiopathic thrombocytopenic purpura: administration of 6 million units of recombinant IFN alpha-2bIntern Med19923112134313471300169
   PubMed Web of Science ®Google Scholar
• BroxAGHowson-JanKFauserAATreatment of idiopathic thrombocytopenic purpura with ascorbateBr J Haematol19887033413443207627
   PubMed Web of Science ®Google Scholar
• KuterDMilestones in understanding platelet production: a historical overviewBr J Haematol2014165224825824528208
   PubMed Web of Science ®Google Scholar
• WendlingFMaraskovskyEDebiliNcMpl ligand is a humoral regulator of megakaryocytopoiesisNature199436964815715748202160
   PubMed Web of Science ®Google Scholar
• KaushanskyKLokSHollyRDPromotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietinNature199436964815685718202159
   PubMed Web of Science ®Google Scholar
• de SauvageFJHassPESpencerSDStimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligandNature199436964815335388202154
   PubMed Web of Science ®Google Scholar
• KuterDJBeelerDLRosenbergRDThe purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet productionProc Natl Acad Sci U S A1994912311104111087972018
   PubMed Web of Science ®Google Scholar
• BasserRLRaskoJEClarkeKThrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancerLancet19963489037127912818909381
   PubMed Web of Science ®Google Scholar
• Vadhan-RajSVerschraegenCFBueso-RamosCRecombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancerAnn Intern Med2000132536436810691586
   PubMed Web of Science ®Google Scholar
• KomatsuNOkamotoTYoshidaTPegylated recombinant human megakaryocyte growth and development factor increased platelet count in patients with aplastic anemia and myelodysplastic syndromeBlood200096296a
   Web of Science ®Google Scholar
• RiceLNicholJLMcMillanRRoskosLKBacileMCyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapyAm J Hematol200168321021411754405
   PubMed Web of Science ®Google Scholar
• GoodnoughLTKuterDJMcCulloughJProphylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietinBlood20019851346135111520781
   PubMed Web of Science ®Google Scholar
• KuterDJGoodnoughLTRomoJThrombopoietin therapy increases platelet yields in healthy platelet donorsBlood20019851339134511520780
   PubMed Web of Science ®Google Scholar
• Vadhan-RajSKavanaghJJFreedmanRSSafety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over studyLancet200235993242145215212090979
   PubMed Web of Science ®Google Scholar
• LiJYangCXiaYThrombocytopenia caused by the development of antibodies to thrombopoietinBlood200198123241324811719360
   PubMed Web of Science ®Google Scholar
• CwirlaSEBalasubramanianPDuffinDJPeptide agonist of the thrombopoietin receptor as potent as the natural cytokineScience19972765319169616999180079
   PubMed Web of Science ®Google Scholar
• BroudyVCLinNLAMG531 stimulates megakaryopoiesis in vitro by binding to MplCytokine2004252526014693160
   PubMed Web of Science ®Google Scholar
• KuterDJBusselJBLyonsRMEfficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trialLancet2008371961039540318242413
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA)FDA drug safety communication: modified risk evaluation and mitigation strategies (REMS) for Nplate (romiplostim) and Promacta (eltrombopag) [web page on the Internet]Rockville, MDFDA1262011 [updated December 15, 2011]. Available from: http://www.fda.gov/drugs/drugsafety/ucm280165/htmAccessed August 8, 2014
   Google Scholar
• BusselJBKuterDJGeorgeJNAMG 531, a thrombopoiesis-stimulating protein, for chronic ITPN Engl J Med2006355161672168117050891
   PubMed Web of Science ®Google Scholar
• KuterDJRummelMBocciaRRomiplostim or standard of care in patients with immune thrombocytopeniaN Engl J Med2010363201889189921067381
   PubMed Web of Science ®Google Scholar
• KuterDJBusselJBNewlandALong-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacyBr J Haematol2013161341142323432528
   PubMed Web of Science ®Google Scholar
• KhellafMMichelMQuittetPRomiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use programBlood2011118164338434521832276
   PubMed Web of Science ®Google Scholar
• GeorgeJNMathiasSDGoRSImproved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trialsBr J Haematol2009144340941519016720
   PubMed Web of Science ®Google Scholar
• MichelMte BoekhorstPAJanssensAReduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostimHematology201116527427721902890
   PubMed Web of Science ®Google Scholar
• GhadakiBNaziIKeltonJGArnoldDMSustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonistsTransfusion201353112807281223451917
   PubMed Web of Science ®Google Scholar
• ZengYDuanXXuJNiXTPO receptor agonist for chronic idiopathic thrombocytopenic purpuraCochrane Database Syst Rev20117CD00823521735426
   PubMed Web of Science ®Google Scholar
• GernsheimerTBGeorgeJNAledortLMEvaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP)J Thromb Haemost2010861372138220230419
   PubMed Web of Science ®Google Scholar
• SalehMNBusselJBChengGEXTEND Study GroupSafety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND studyBlood2013121353754523169778
   PubMed Web of Science ®Google Scholar
• MahévasMFainOEbboMThe temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational studyBr J Haematol2014165686586924725224
   PubMed Web of Science ®Google Scholar
• LevenEHsiehLRamaswamyKMcGuinnCENugentDBusselJBSafe and effective use of romiplostim and eltrombopag in children with ITPASH Annual Meeting Abstracts2013311 Abstract 3541
   Google Scholar
• GhanimaWJunkerPHasselbalchHCFibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agentsBr J Haematol2011155224825521902682
   PubMed Web of Science ®Google Scholar
• BoiocchiLOraziAGhanimaWArabadjiefMBusselJBGeyerJTThrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalitiesMod Pathol2012251657421841770
   PubMed Web of Science ®Google Scholar
• BusselJBKuterDJPullarkatVLyonsRMGuoMNicholJLSafety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITPBlood2009113102161217118981291
   PubMed Web of Science ®Google Scholar
• KuterDJMuftiGJBainBJHasserjianRPDavisWRutsteinMEvaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostimBlood2009114183748375619671919
   PubMed Web of Science ®Google Scholar
• EttrupMSJensenAØEngebjergMCBone marrow reticulin and collagen content in patients with adult chronic immune thrombocytopenic purpura: a Danish nationwide studyAm J Hematol2010851293093420981681
   PubMed Web of Science ®Google Scholar
• BeckmanENBrownAWJrNormal reticulin level in iliac bone marrowArch Pathol Lab Med199011412124112432252420
   PubMed Web of Science ®Google Scholar
• BauermeisterDEQuantitation of bone marrow reticulin-a normal rangeAm J Clin Pathol197156124315556211
   PubMed Web of Science ®Google Scholar
• KuterDJThe biology of thrombopoietin and thrombopoietin receptor agonistsInt J Hematol2013981102323821332
   PubMed Web of Science ®Google Scholar
• GiagounidisAMuftiGJFenauxPResults of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopeniaCancer2014120121838184624706489
   PubMed Web of Science ®Google Scholar
• BusselJBBuchananGRNugentDJA randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopeniaBlood20111181283621502541
   PubMed Web of Science ®Google Scholar
• ElalfyMSAbdelmaksoudAAEltonbaryKYRomiplostim in children with chronic refractory ITP: randomized placebo controlled studyAnn Hematol201190111341134421318572
   PubMed Web of Science ®Google Scholar
• TarantinoMDBusselJBGeddisASafety and efficacy of long-term open-label romiplostim dosing in thrombocytopenic pediatric patients with immune thrombocytopenia (ITP)Blood2013122213530
   Web of Science ®Google Scholar
• PasquetMAladjidiNGuitonCCentre de Référence National des Cytopénies Auto-immunes de l’Enfant (CEREVANCE)Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experienceBr J Haematol2014164226627124152194
   PubMed Web of Science ®Google Scholar
• AmgenSafety and efficacy study of romiplostim (AMG 531) to treat ITP in pediatric subjectsClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2007 [updated July 18, 2014]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00515203. NLM identifier: NCT00515203Accessed August 24, 2014
   Google Scholar
• MD Anderson Cancer CenterAMG 531 in patients with advanced malignancy receiving treatment with carboplatinClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2005 [updated April 7, 2014]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00147225. NLM identifier: NCT00147225Accessed August 24, 2014
   Google Scholar
• MD Anderson Cancer CenterStudy of AMG 531 to evaluate the safety and efficacy in patients with non-Hodgkin’s lymphomaClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2006 [updated September 4, 2014]. Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT00299182. NLM identifier: NCT00299182Accessed August 24, 2014
   Google Scholar
• Memorial Sloan-Kettering Cancer CenterStudy of romiplostim versus observation for chemotherapy induced thrombocytopeniaClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2014 [updated August 14, 2014]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT02052882?term=soff+romiplostim&rank=1. NLM identifier: NCT02052882Accessed October 12, 2014
   Google Scholar
• New York University School of MedicineRomiplostim in increasing low platelet counts in patients with multiple myeloma receiving chemotherapyClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2012 [updated September 12, 2014]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01676961. NLM identifier: NCT01676961Accessed August 24, 2014
   Google Scholar
• AmgenDose/Schedule finding trial of romiplostim for chemotherapy-induced thrombocytopenia (CIT) in non-small cell lung cancer (NSCLC)ClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2006 [updated September 18, 2013]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00413283. NLM identifier: NCT00413283Accessed August 24, 2014
   Google Scholar
• AmgenNplate® pregnancy exposure registry (NPER)ClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2014 [updated June 24, 2014]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT02090088. NLM identifier: NCT02090088Accessed August 24, 2014
   Google Scholar
• Kyowa Hakko Kirin Korea Co, LtdA phase 2 study to evaluate the efficacy and safety of AMG531 in aplastic anemiaClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2014 [updated March 20, 2014]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT02094417. NLM identifier: NCT02094417Accessed August 24, 2014
   Google Scholar
• University of Southern CaliforniaRomiplostim in treating hepatitis c-infected patients with thrombocytopeniaClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 [updated July 22, 2014]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01153919. NLM identifier: NCT01153919Accessed August 24, 2014
   Google Scholar